Össur hf
Market Cap
ø19.5b
Last Updated
2019/10/18 21:13 UTC
Data Sources
Company Financials +
Executive Summary
Össur hf., together with its subsidiaries, develops, produces, and sells non-invasive orthopedic products in Europe, the Middle-East, Africa, the Americas, and the Asia-Pacific.
Snowflake
Fundamentals
Acceptable track record with mediocre balance sheet.
Similar Companies
Share Price & News
How has Össur hf's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.9%
OSSR
0.9%
DK Medical Equipment
0.5%
DK Market
1 Year Return
37.9%
OSSR
6.2%
DK Medical Equipment
10.7%
DK Market
Return vs Industry: OSSR exceeded the Danish Medical Equipment industry which returned 6.2% over the past year.
Return vs Market: OSSR exceeded the Danish Market which returned 10.7% over the past year.
Shareholder returns
| OSSR | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.9% | 0.9% | 0.5% |
| 30 Day | -11.0% | -4.7% | -1.2% |
| 90 Day | 8.8% | -3.8% | 0.9% |
| 1 Year | 38.5%37.9% | 7.7%6.2% | 14.1%10.7% |
| 3 Year | 80.7%78.2% | 65.7%57.6% | 32.9%21.7% |
| 5 Year | 178.4%171.8% | 107.5%89.5% | 67.9%43.9% |
Price Volatility Vs. Market
How volatile is Össur hf's share price compared to the market and industry in the last 5 years?
Simply Wall St News
8 months ago | Simply Wall St
With A 14% Return On Equity, Is Össur hf. (CPH:OSSR) A Quality Stock?10 months ago | Simply Wall St
What Should Investors Know About Össur hf's (CPH:OSSR) Return On Capital?11 months ago | Simply Wall St
How Does Össur hf's (CPH:OSSR) Earnings Growth Stack Up Against Industry Performance?Valuation
Is Össur hf undervalued compared to its fair value and its price relative to the market?
33.56x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Undervalued: OSSR (DKK46.2) is trading above our estimate of fair value (DKK35.99)
Significantly Undervalued: OSSR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: OSSR is poor value based on its PE Ratio (33.6x) compared to the Medical Equipment industry average (33.6x).
PE vs Market: OSSR is poor value based on its PE Ratio (33.6x) compared to the Danish market (14.7x).
Price to Earnings Growth Ratio
Low PEG Ratio: OSSR is poor value based on its PEG Ratio (2.7x)
Price to Book Ratio
PB vs Industry: OSSR is good value based on its PB Ratio (5.3x) compared to the DK Medical Equipment industry average (6.7x).
Next Steps
Future Growth
How is Össur hf forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
12.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OSSR's forecast earnings growth (12.4% per year) is above the savings rate (0.2%).
Earnings vs Market: OSSR's earnings (12.4% per year) are forecast to grow faster than the Danish market (12.1% per year).
High Growth Earnings: OSSR's earnings are forecast to grow, but not significantly.
Revenue vs Market: OSSR's revenue (7.1% per year) is forecast to grow slower than the Danish market (6.8% per year).
High Growth Revenue: OSSR's revenue (7.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: OSSR's Return on Equity is forecast to be low in 3 years time (14.3%).
Next Steps
Past Performance
How has Össur hf performed over the past 5 years?
7.6%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: OSSR's earnings have grown by 7.6% per year over the past 5 years.
Accelerating Growth: OSSR's earnings growth over the past year (32.5%) exceeds its 5-year average (7.6% per year).
Earnings vs Industry: OSSR earnings growth over the past year (32.5%) exceeded the Medical Equipment industry 13.1%.
Return on Equity
High ROE: OSSR's Return on Equity (15.7%) is considered low.
Return on Assets
ROA vs Industry: OSSR's Return on Assets is below or equal to the Medical Equipment industry average last year.
Return on Capital Employed
ROCE Improving: OSSR's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is Össur hf's financial position?
Financial Position Analysis
Short Term Liabilities: OSSR's short term assets ($278.1M) exceeds its short term liabilities ($131.3M)
Long Term Liabilities: OSSR's short term assets (278.1M) do not cover its long term liabilities (337.7M)
Debt to Equity History and Analysis
Debt Level: OSSR's debt to equity ratio (40.8%) is considered high
Reducing Debt: OSSR's debt to equity ratio has increased from 30.1% to 40.8% over the past 5 years.
Debt Coverage: OSSR's debt is well covered by operating cash flow (37.4%).
Interest Coverage: OSSR's interest payments on its debt are well covered by EBIT (17.6x coverage).
Balance Sheet
Inventory Level: OSSR has a high level of physical assets or inventory.
Debt Coverage by Assets: OSSR's debt is covered by short term assets (assets are 1.233140x debt).
Next Steps
Dividend
What is Össur hf's current dividend yield, its reliability and sustainability?
0.30%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: OSSR's dividend (0.3%) isn’t notable compared to the bottom 25% of dividend payers in the Danish market (1.74%).
High Dividend: OSSR's dividend (0.3%) is low compared to the top 25% of dividend payers in the Danish market (5.05%).
Stable Dividend: OSSR is not paying a notable dividend for the Danish market, therefore no need to check if payments are stable.
Growing Dividend: OSSR is not paying a notable dividend for the Danish market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: OSSR is not paying a notable dividend for the Danish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OSSR's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.
Next Steps
Management
What is the CEO of Össur hf's salary, the management and board of directors tenure and is there insider trading?
5.0yrs
Average management tenure
CEO
Jón Sigurdsson (63yo)
23.8yrs
Tenure
US$2,062,000
Compensation
Mr. Jón Sigurdsson has been the Chief Executive Officer and President of Gibaud SAS since 1996. Mr. Sigurdsson has been Senior Vice President of Procurement at Promens Canada Inc. and Promens hf. since Jul ...
CEO Compensation Analysis
Compensation vs. Market: Jón's total compensation ($USD2.06M) is about average for companies of similar size in the Danish market ($USD2.03M).
Compensation vs Earnings: Jón's compensation has been consistent with company performance over the past year.
Management Age and Tenure
5.0yrs
Average Tenure
50yo
Average Age
Experienced Management: OSSR's management team is seasoned and experienced (5 years average tenure).
Board Age and Tenure
10.8yrs
Average Tenure
62yo
Average Age
Experienced Board: OSSR's board of directors are seasoned and experienced ( 10.8 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Jón Sigurdsson (63yo)
CEO & President
- Tenure: 23.8yrs
- Compensation: US$2.06m
Ossur Kristinsson (76yo)
- Tenure: 0yrs
- Compensation: US$25.00k
Egill Jónsson (62yo)
Executive Vice President of Manufacturing & Operations
- Tenure: 0yrs
- Compensation: US$444.00k
Ólafur Gylfason (50yo)
Executive Vice President of Sales & Marketing
- Tenure: 3.7yrs
- Compensation: US$600.00k
Sigurborg Arnarsdottir
Compliance Officer
- Tenure: 17.8yrs
Sveinn Sölvason (41yo)
Chief Financial Officer
- Tenure: 6.4yrs
- Compensation: US$221.00k
Margrét Friðriksdóttir (41yo)
Executive Vice President of Human Resources & Corporate Strategy
- Tenure: 0yrs
- Compensation: US$242.00k
Kim de Roy (42yo)
Executive Vice President of Research & Development
- Tenure: 1.9yrs
Gudjon Karason (50yo)
Executive Vice President of Clinics
- Tenure: 1.9yrs
David Hreidarsson
Investor Relations Manager
- Tenure: 0yrs
Board Members
Niels Jacobsen (62yo)
Chairman of the Board
- Tenure: 13.8yrs
- Compensation: US$94.00k
Kristján Ragnarsson (76yo)
Vice Chairman
- Tenure: 7.6yrs
- Compensation: US$56.00k
Svafa Grönfeldt (54yo)
Director
- Tenure: 11.8yrs
- Compensation: US$38.00k
Guðbjörg Eggertsdóttir (68yo)
Director
- Tenure: 6.6yrs
- Compensation: US$38.00k
Arne Nielsen (51yo)
Director
- Tenure: 10.8yrs
- Compensation: US$38.00k
Company Information
Össur hf.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Össur hf.
- Ticker: OSSR
- Exchange: CPSE
- Founded: 1971
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: ø19.534b
- Shares outstanding: 422.82m
- Website: https://www.ossur.com
Number of Employees
Location
- Össur hf.
- Grjothals 1 - 5
- Reykjavik
- 110
- Iceland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 0FIW | LSE (London Stock Exchange) | Yes | Common Stock | GB | DKK | Oct 1999 |
| OSSR | CPSE (OMX Nordic Exchange Copenhagen) | Yes | Common Stock | DK | DKK | Oct 1999 |
| OSSRC | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Common Stock | GB | DKK | Oct 1999 |
| OSSF.F | OTCPK (Pink Sheets LLC) | Yes | Common Stock | US | USD | Oct 1999 |
| OSSU.Y | OTCPK (Pink Sheets LLC) | SPONSORED ADR | US | USD | Dec 2011 |
Biography
Össur hf., together with its subsidiaries, develops, produces, and sells non-invasive orthopedic products in Europe, the Middle-East, Africa, the Americas, and the Asia-Pacific. The company’s prosthetics p ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/18 21:13 |
| End of Day Share Price | 2019/10/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.